Stereotaxis, Inc. (STXS)

NYSEAMERICAN: STXS · Real-Time Price · USD
1.790
-0.030 (-1.65%)
At close: Mar 20, 2026, 4:00 PM EDT
1.830
+0.040 (2.23%)
Pre-market: Mar 23, 2026, 5:11 AM EDT
Market Cap174.08M +13.5%
Revenue (ttm)32.38M +20.3%
Net Income-22.91M
EPS-0.25
Shares Out 97.25M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume645,015
Open1.820
Previous Close1.820
Day's Range1.760 - 1.890
52-Week Range1.540 - 3.590
Beta1.40
AnalystsStrong Buy
Price Target4.00 (+123.46%)
Earnings DateMar 9, 2026

About STXS

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Na... [Read more]

Sector Healthcare
IPO Date Aug 12, 2004
Employees 131
Stock Exchange NYSEAMERICAN
Ticker Symbol STXS
Full Company Profile

Financial Performance

In 2025, Stereotaxis's revenue was $32.38 million, an increase of 20.28% compared to the previous year's $26.92 million. Losses were -$22.91 million, -9.62% less than in 2024.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for STXS stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 123.46% from the latest price.

Price Target
$4.0
(123.46% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Stereotaxis: Medical Robotics Upside Offsets Cash Burn And Execution Risks

Stereotaxis targets early-stage endovascular robotics with differentiated magnetic navigation for electrophysiology and other minimally invasive procedures. Their MAGiC catheter recently received FDA ...

9 days ago - Seeking Alpha

Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript

Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript

13 days ago - Seeking Alpha

Stereotaxis Reports 2025 Full Year Financial Results

ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resu...

13 days ago - GlobeNewsWire

Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026

ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

5 weeks ago - GlobeNewsWire

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of ...

5 weeks ago - GlobeNewsWire

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U....

2 months ago - GlobeNewsWire

Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference

ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the compa...

4 months ago - GlobeNewsWire

Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript

Stereotaxis, Inc. ( STXS) Q3 2025 Earnings Call November 11, 2025 4:30 PM EST Company Participants David Fischel - CEO & Chairman Kimberly Peery - Chief Financial Officer Conference Call Participants...

4 months ago - Seeking Alpha

Stereotaxis Reports 2025 Third Quarter Financial Results

ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...

4 months ago - GlobeNewsWire

GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance

ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it receiv...

4 months ago - GlobeNewsWire

Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025

ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

5 months ago - GlobeNewsWire

Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs

ST. LOUIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE...

5 months ago - GlobeNewsWire

Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias

ST. LOUIS and MARLBOROUGH, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, and Car...

5 months ago - GlobeNewsWire

Erasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System

ST. LOUIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced successful fi...

6 months ago - GlobeNewsWire

First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter

ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the successfu...

7 months ago - GlobeNewsWire

Stereotaxis to Present at Upcoming Investor Conferences

ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fi...

7 months ago - GlobeNewsWire

Stereotaxis Technology to be Featured at Heart Rhythm Society's HRX 2025

ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology...

7 months ago - GlobeNewsWire

Stereotaxis, Inc. (STXS) Q2 2025 Earnings Call Transcript

Stereotaxis, Inc. (NYSE:STXS) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David Leo Fischel - CEO & Chairman Kimberly R. Peery - Chief Financial Officer Conference...

8 months ago - Seeking Alpha

Stereotaxis Reports 2025 Second Quarter Financial Results

ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...

8 months ago - GlobeNewsWire

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter

ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has re...

8 months ago - GlobeNewsWire

Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025

ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

8 months ago - GlobeNewsWire

Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock

ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has e...

8 months ago - GlobeNewsWire

Stereotaxis: Recurring Revenue Inflection

I rate Stereotaxis Strong Buy, with 85% upside to $4 PT, driven by underappreciated recurring revenue and regulatory catalysts. Recurring revenue is inflecting above 25% growth, with high-margin dispo...

9 months ago - Seeking Alpha

First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology

ST. LOUIS, July 01, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publicatio...

9 months ago - GlobeNewsWire

Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript

Stereotaxis, Inc. (NYSE:STXS) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kim Peery - Chief Financial Officer Conference Call Partic...

11 months ago - Seeking Alpha